PULMATRiX

Recent News

AAA8 – 2018 – Efficacy of PUR1900, An Inhaled Antifungal Therapy, in a Guinea Pig Model of Invasive Pulmonary Aspergillosis / PDF

(200 KB)

Investor Alerts

Nov 12, 2020

Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented...

Oct 21, 2020

Pulmatrix Announces Commercial Launch of FEND, an OTC Nasal Hygiene Product Proven to Reduce Airborne Respiratory Droplets, with Partner Sensory Cloud

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and non-pulmonary disease using its patented iSPERSE™...

Sep 30, 2020

Pulmatrix Announces Publication Demonstrating Reduction of Bioaerosols with FEND, an OTC Nasal Hygiene Product Designed to Cleanse Airways of Airborne Particles

LEXINGTON, Mass., Sept. 30, 2020 /PRNewswire/ – Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary and...

Events

Cowen Healthcare Conference

Wednesday, March 9, 2016

11:20am - 11:50am EST

Biotech Showcase 2016

Monday, January 11, 2016

5:30pm - 6:00pm EST

about us